BioWorld Asia

April 1, 2009

Intercell Gets Stock Boost as FDA Approves Ixiaro

Shares in Intercell AG received a significant boost Tuesday on news that the FDA approved its Japanese Encephalitis Virus (JEV) vaccine Ixiaro late Monday. (BioWorld International) Read More

BioVex Raises $40M to Fund Melanoma Vaccine Study

More Breast Cancer Genes to Boost Genetic Screening

EU Animal Directive Draws Ire from UK Researchers

Survey Points to Trouble Raising Funds in the UK

TcLand, Genedata Collaborate on Autoimmune Biomarkers

Newron Moves Ralfinamide into Pivotal Pain Trials

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 9, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...